AI Article Synopsis
- Acute kidney injury (AKI) has high mortality rates, largely due to the challenges in timely treatment and poor drug delivery to the kidneys.
- Researchers developed polyvinylpyrrolidone-curcumin nanoparticles (PCurNP) that target the kidneys effectively, specifically engineered to be small enough for renal excretion.
- In studies, the smallest nanoparticles (Zr-PCurNP M10) showed significantly better kidney accumulation and were effective in treating AKI caused by cisplatin, highlighting their potential for improved drug delivery.
Article Abstract
Acute kidney injury (AKI) leads to unacceptably high mortality due to difficulties in timely intervention and less efficient renal delivery of therapeutic drugs. Here, a series of polyvinylpyrrolidone (PVP)-curcumin nanoparticles (PCurNP) are designed to meet the renal excretion threshold (∼45 kDa), presenting a controllable delivery nanosystem for kidney targeting. Renal accumulation of the relatively small nanoparticles, Zr-PCurNP M10 with the diameter between 5 and 8 nm, is found to be 1.7 times and 1.8 times higher than the accumulation of Zr-PCurNP M29 (20-50 nm) and M40 (20-50 nm) as revealed by PET imaging. Furthermore, serum creatinine analysis, kidney tissues histology, and tubular injury scores revealed that PCurNP M10 efficiently treated cisplatin-induced AKI. Herein, PCurNP offers a novel and simple strategy for precise PET image-guided drug delivery of renal protective materials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058893 | PMC |
| http://dx.doi.org/10.1016/j.bioactmat.2022.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!